ArticleBiochemistry and biophysics reports2026
Evaluation of oxidative stress and coagulation factors in MS patients throughout both relapse and remission stages.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Relapsing-remitting Multiple Sclerosis (RRMS) is characterized by inflammatory attacks on myelin. Previous studies have shown the vital role of coagulation factors, inflammation, and oxidative stress in multiple sclerosis (MS). Hence, changes in these factors in relapse occurrence could propose novel therapeutic and diagnostic targets.The blood samples were collected during relapse status. Then, patients were followed up for three months with no difference in disease modifying treatments (DMTs)-naive status, and the second blood samples were collected in the remission phase. Methods: The coagulation factors were measured in 24 RRMS (13F/11M) patients and 24 healthy controls (12F/12 M). Oxidative stress markers such as total oxidant status (TOS), malondialdehyde (MDA), total antioxidant capacity (TAC) and inflammatory biomarkers such as IL-6, ferritin, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured in both relapse and remission phases. Results: The expanded disability status scale (EDSS) was considerably higher in relapse versus remission status (p = 0.001). The results indicate that d-dimer, as a coagulation marker, ferritin, CRP, ESR, MDA, and TOS are higher in relapse vs remission (p < 0.05). Besides, further analysis showed that fibrinogen, ferritin, IL-6, and TOS were significantly different in RRMS vs the control (p < 0.05). These parameters showed no significant correlation between EDSS with coagulation, inflammatory, and oxidative markers (p > 0.05). Conclusion: Our results showed that the levels of fibrinogen, TOS, ferritin, and IL-6 may have diagnostic efficacy in MS vs control. This study has some limitations. The first was the follow-up of RRMS candidates in relapse and remission. The second is that we did not measure the coagulation, inflammatory, and oxidative markers in the CSF sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.